|
TOP NEWS
POLICY & REGULATION
LITIGATION
Celgene Gets Final OK For $239M Deal, Atty Fees
By Emilie Ruscoe
Investors in biopharmaceutical company Celgene Corp. have gotten a final nod for their $239 million deal to end proposed class claims that the company overstated commercial prospects for two of its drugs, and the investors' four-firm legal team will get fees and costs of nearly $57.3 million for their work on the case.
2 documents attached |
Read full article »
| Save to favorites »
PEOPLE
EXPERT ANALYSIS
4 Emerging Approaches To AI Protective Order Language
Over the last year, at least five federal district courts have issued or analyzed specific protective order provisions restricting the use of generative artificial intelligence platforms with protected materials, establishing that proactive AI-specific provisions are now standard practice and demonstrating that no single model works for every case, says Joel Bush at Kilpatrick.
Read full article »
| Save to favorites »
LEGAL INDUSTRY
|